Seaport Therapeutics and Hemab Therapeutics filed S-1 registration statements with the SEC this week while Kailera Therapeutics priced its offering at $7.50 per share, raising $50 million before underwriter options. The trio represents the first cluster of biotech IPO activity since May 2023, when market conditions forced fourteen similar filings into withdrawal or indefinite postponement.
Seaport, a Massachusetts-based neuropsychiatry platform backed by Atlas Venture and Sofinnova, disclosed $287 million in total capital raised across four rounds. The company's lead candidate targets treatment-resistant depression with a novel GABA-A modulator, currently in Phase 2b. Hemab, developing hemophilia gene therapies out of Philadelphia, listed Bain Capital Life Sciences and OrbiMed as anchor investors with $195 million committed since inception. Kailera's pricing came at the low end of its proposed $7.50-$9.50 range, with Leerink Partners and TD Cowen as joint bookrunners. The company plans to allocate proceeds toward advancing its lead oncology program through Phase 1 safety studies by Q3 2025.
The filings arrive as the biotech IPO index climbed 11.3% in Q1 2025, reversing eight consecutive quarters of net outflows. Allocators have been testing receptivity with small tranches—Kailera's $50 million raise is 40% below the $84 million median for comparable-stage oncology IPOs in 2021. The timing suggests underwriters believe a narrow band of institutional buyers will support clinical-stage platforms with defined near-term catalysts, particularly in CNS and rare disease verticals where recent M&A activity has validated asset classes. Seaport's depression program competes in a space where Sage Therapeutics exited with a $435 million acquisition in November, and Hemab's gene therapy approach follows Pfizer's $1.2 billion purchase of a hemophilia B candidate three months prior.
What matters for allocators is whether these three can hold post-IPO valuations long enough to complete their Phase 2 readouts. If Seaport or Hemab file follow-on offerings within twelve months—typical for biotechs burning $60-80 million annually—it signals the window reopened for capital rotation, not fundamental risk appetite. Kailera's pricing at the range floor indicates bookrunners are building in a 15-20% discount for volatility absorption. The real test will be secondary trading volumes in week two and whether retail participation stays below 12% of float, the threshold where momentum-chasing typically destabilizes these names.
Watch for Seaport and Hemab's roadshow schedules, expected within 21 days of effective S-1 dates. If either company prices above midpoint or increases share count, it confirms institutional demand for clinical-stage risk is rebuilding. Track Kailera's stock performance through its first earnings call in late May—any guidance revision on trial timelines will set comps for the next wave of biotech listings already in confidential filing status.